The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised orforglipron (Foundayo), making it the first country in Europe to approve the GLP-1 tablet for both weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased physical activity, orforglipron is authorised for weight loss and weight maintenance in adults in the UK […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!